Drug
Sar-Arg-Val-Tyr-Ile-His-Pro-Ala-OH clinical trials
Also written TRV027 and TRV120027.
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2010 (1)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2011 | 1 |
| 2013 | 1 |
| 2020 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 2
Trevena Inc. (3) · Sean Collins (1) · Imperial College London (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Sar-Arg-Val-Tyr-Ile-His-Pro-Ala-OH is read from its arms, and is right about nine times in ten.
Testing it · 5
- Novel Experimental COVID-19 Therapies Affecting Host ResponseCompletedPhase 2/3Sean CollinsNCT04924660Written as TRV027
- RAS and Coagulopathy in COVID19CompletedEarly Phase 1Imperial College LondonNCT04419610Written as TRV027
- A Study to Explore the Efficacy of TRV027 in Patients Hospitalized for Acute Decompensated Heart FailureCompletedPhase 2Trevena Inc.NCT01966601Written as TRV027 Dose #1
- Study to Evaluate the Effects of TRV120027 in Patients With Heart FailureCompletedPhase 1/2Trevena Inc.NCT01187836Written as TRV120027
- Study to Evaluate TRV120027 on Renal Pharmacodynamics in Patients With Heart Failure and Renal DysfunctionCompletedPhase 1Trevena Inc.NCT01444872Written as TRV120027
Codes
What other systems call Sar-Arg-Val-Tyr-Ile-His-Pro-Ala-OH · ClinicalTrials.gg INT005771
- MeSH (NLM) C555534Sar-Arg-Val-Tyr-Ile-His-Pro-Ala-OHOne source NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C555534 | Sar-Arg-Val-Tyr-Ile-His-Pro-Ala-OH | One source NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.